Christina Ackermann compensation by year
Bausch Health Companies Summary Compensation Table · all 7 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Salary | $230,769 | $600,000 | $647,539 | $690,308 | $743,654 | $750,000 | $750,000 |
| Bonus | $1,800,000 | $0 | $0 | $0 | $0 | $0 | — |
| Stock awards | $2,109,143 | $906,030 | $723,176 | $1,343,982 | $1,692,387 | $2,348,225 | $2,063,144 |
| Option awards | $599,987 | $360,006 | $359,964 | $525,050 | $540,362 | $600,033 | $1,499,999 |
| Non-equity incentive | $0 | $636,000 | $892,320 | $806,400 | $540,000 | $862,000 | $402,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $13,306 | $293,116 | $763,908 | $14,192 | $24,625 | $14,330 | $20,383 |
| Total | $4,753,204 | $2,795,152 | $3,386,907 | $3,379,932 | $3,541,028 | $4,574,588 | $4,735,526 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Bausch Health Companies Inc. DEF 14A filed April 6, 2023, accession 0001140361-23-017057, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Bausch Health Companies Inc. filed document, accession 0001140361-23-017057. Every figure is read from that document and cited to the page and table it appears in. Filed April 6, 2023.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 83,333 | $1,292,495 | — |
| RSU | 35,000 | $542,850 | — |
| RSU | 14,104 | $88,573 | — |
| RSU | 13,182 | $82,783 | — |
| RSU | 12,447 | $78,167 | — |
| RSU | 10,985 | $68,986 | — |
| RSU | 9,391 | $58,975 | — |
| RSU | 7,645 | $48,011 | — |
| RSU | 6,483 | $40,713 | — |
| RSU | 1,464 | $9,194 | — |
| Option | 34,928 | — | $32.56 |
| Option | 27,291 | — | $24.77 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Bausch Health Companies Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 13 award rows shown.
Bausch Health Companies’s named executive officers, FY2022
as the company reported each| Named executive officer | Role | FY2022 total |
|---|---|---|
| Joseph Papa | Former Chief Executive Officer | $19,781,761 |
| Thomas Appio | Chief Executive Officer | $13,171,461 |
| Tom Vadaketh | Executive Vice President and Chief Financial Officer | $9,011,699 |
| Sam Eldessouky | Former Executive Vice President and Chief Financial Officer | $6,152,073 |
| Christina Ackermann · this page | Former Executive Vice President and General Counsel and Head of Commercial Operations | $4,735,526 |
| Robert Spurr | Former President US Pharmaceutical Business | $4,303,097 |
| Seana Carson | Executive Vice President and General Counsel | $4,212,695 |
The full Bausch Health Companies compensation record
free company briefThis page is one person within Bausch Health Companies's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Bausch Health Companies proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Bausch Health Companies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.